公共卫生紧急事件期间开展中枢神经系统试验——COVID-19大流行的经验教训:ISCTM/ECNP联合工作组共识文件
国际中枢神经系统临床试验与方法学学会(ISCTM)与欧洲神经精神药理学院(ECNP)于2020年下半年成立联合工作组,探讨减轻COVID-19对临床试验影响的可能途径,同时推进将新疗法带给患者的方法与能力。工作组任务是制定试验设计修改指南,帮助申办公司最小化数据完整性风险,重点聚焦与COVID-19相关的监管、技术、操作和方法学问题。为便于提出聚焦且可迁移的建议,选取神经退行性疾病与痴呆、精神健康障碍、罕见/儿科疾病三个疾病类别作为示例,展示中枢神经系统临床试验中已实施的解决方案的广度及持续挑战。本文描述工作组的 interim 建议以及未来公共卫生紧急事件的优先事项,为中枢神经系统试验开发与实施中的永久采纳提供信息。
要点
- ISCTM与ECNP于2020年下半年成立联合工作组,制定试验设计修改指南以最小化COVID-19期间数据完整性风险。
- 工作组聚焦监管、技术、操作和方法学四类问题,提出可迁移的建议。
- 选取神经退行性疾病与痴呆、精神健康障碍、罕见/儿科疾病三个疾病类别作为示例,展示解决方案的广度与持续挑战。
- 本文描述工作组的 interim 建议及未来公共卫生紧急事件的优先事项,以 inform 中枢神经系统试验开发与实施中的永久采纳。
适用人群与场景
- 中枢神经系统临床试验的申办公司及相关研究人员
- 神经退行性疾病与痴呆、精神健康障碍、罕见/儿科疾病三个疾病类别的试验
研究设计与关键结果
- ISCTM与ECNP于2020年下半年成立联合工作组,任务是制定试验设计修改指南,帮助申办公司最小化数据完整性风险。
- 工作组聚焦与COVID-19相关的监管、技术、操作和方法学问题。
- 选取神经退行性疾病与痴呆、精神健康障碍、罕见/儿科疾病三个疾病类别作为示例,展示中枢神经系统临床试验中已实施的解决方案的广度及持续挑战。
- 本文描述工作组的 interim 建议以及未来公共卫生紧急事件的优先事项,为中枢神经系统试验开发与实施中的永久采纳提供信息。
证据类型、等级与局限
- 证据类型:共识文件(joint working group consensus paper)
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未据此给出推荐
指南或共识出处
- Conducting CNS trials during a public health emergency - Lessons learned from the COVID-19 pandemic: A joint ISCTM/ECNP working group consensus paper
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
A joint working group between the International Society of CNS Clinical Trials and Methodology (ISCTM) and the European College of Neuropsychopharmacology (ECNP) was formed in the latter part of 2020 to explore possible ways to mitigate the impact of Coronavirus disease-19 (COVID-19) in clinical trials while attempting to advance approaches and capabilities to bring new therapeutics to patients. The working group was tasked with developing guidelines for trial design modifications to assist sponsor companies in minimizing risks to data integrity, with a focus on regulatory, technological, operational, and methodological issues related to COVID-19. To facilitate focused and transferable recommendations, three disease categories were selected as examples to demonstrate the breadth of solutions implemented across CNS clinical trials, as well as ongoing challenges. The categories studied reflected the interests and expertise of the working group, and included neurodegenerative diseases and dementia, mental health disorders, and rare/pediatric diseases. Herein, we describe interim recommendations from the working group as well as priorities for future public health emergencies, to inform permanent adoption in CNS clinical trial development and conduct.
参考来源
- Olugemo K, Bugarski-Kirola D, Dawson GR, et al. Conducting CNS trials during a public health emergency - Lessons learned from the COVID-19 pandemic: A joint ISCTM/ECNP working group consensus paper. Neurosci Appl. 2023. PMID: 40476949. doi:10.1016/j.nsa.2023.101129
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。